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Background: Esophageal squamous cell carcinoma (ESCC) is one of the most common and deadly forms of cancer.
Despite advances in the diagnosis and treatment of this cancer, the survival rate at five years is poor. Lately, miR-22
is identified as a tumor-suppressing microRNA in many human cancers. However, the specific function of miR-22 in
ESCC is unclear at this point.
Methods: We first measured miR-22 expression level in 30 paired of ESCC and matched normal tissues, ESCC cell
lines by real-time quantitative RT-PCR. Invasion assay, MTT proliferation assay and wound-healing assay were
performed to test the invasion and proliferation of ESCC cell after overexpression of miR-22.
Results: We found that the expression of miR-22 in ESCC tissues and cell lines were much lower than that in normal
control, respectively. The expression of miR-22 was inversely correlated with ESCC metastatic ability. Furthermore,
transfection of miR-22 expression plasmid could significantly inhibit the cell proliferation, migration and invasion
in Eca109 and Kyse410 ESCC cell lines.
Conclusions: Our findings suggest that miR-22 act as tumor suppressor and inhibiting ESCC cell migration and
invasion. The findings of this study contribute to the current understanding of the functions of miR-22 in ESCC.
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Esophageal cancer, one of the most common malignant
tumors, is the eighth most common cancer and the sixth
most common causes of cancer mortality in the world
[1,2]. Esophageal cancer can be divided into two main
forms: esophageal squamous cell carcinoma (ESCC) and
adenocarcinoma [3]. Adenocarcinoma is common in
western countries but ESCC is predominant in East Asia,
especially in China [1,4]. Although advances have been
made in the treatment of ESCC, including surgery,
chemotherapy, radiation or a combination of these op-
tions, the prognosis of ESCC patients remains very poor,
which the overall 5-year survival rate of patient after sur-
gery is only about 14-22% [5]. In this way, there is a great* Correspondence: xuwei_xy2014@163.com
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unless otherwise stated.need to discover more biomarkers and therapeutic tar-
gets for ESCC.
MicroRNAs (miRNAs), which encode small non-coding
RNAs of approximately 22 nucleotides, are now recognized
as a very large gene family. miRNAs can be classified as
oncogenes or as tumor suppressors, and by targeting vari-
ous transcripts they participate in diverse processes, in-
cluding proliferation, apoptosis, metabolism, and cellular
differentiation, etc. [6]. miR-22 is a 22-nt non-coding RNA
and was originally identified in HeLa cells as a tumor-
suppressing miRNA. Subsequently, miR-22 was identified
to be ubiquitously expressed in a variety of tissues [7]. Re-
cently, several targets of miR-22 were reported to mediate
its tumorsuppressive effect, such as tumor-suppressive
PTEN, Max genes, p21, Sp1, CD147 and oncogene c-Myc
expression, etc. [7-11]. However, the expression and role of
miR-22 in ESCC have not yet been clarified.
In the current study, we validated the differential expres-
sion of miR-22 in ESCC and investigated the function ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 miR-22 is down-expressed in ESCC tissues. (A) The relative levels of miR-22 in thirty paired of ESCC samples were measured by real-time
quantitative RT–PCR, and the U6 small nuclear RNA was used as an internal control. Student’s t test was used to analyze the significant differences
between the tumor and normal tissues. (B) and (C) The expression of miR-22 in metastasis tumors and advanced histologic grades. Student’s t-test was
used to analyze the significant differences.
Figure 2 The relative expression levels of miR-22 in the eight
ESCC cell lines and one normal esophageal epithelial cell lines.
Student’s t-test was used to analyze the significant differences.
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miR-22 might act as a tumor suppressor and serve as a
potential therapeutic target in ESCC. To the best of our
knowledge, this is the first study to examine the expres-
sion and mechanism of miR-22 in ESCC migration and
invasion.
Results
The expression of miR-22 is down-regulated in ESCC
tissues and cell lines
The expression levels of miR-22 were first evaluated in
thirty paired of ESCC and normal tissues by real time
RT-PCR. As showed in Figure 1A, we found that tumor
tissues showed aberrant downregulation of miR-22 com-
pared with adjacent non-tumor tissues (P = 0.0015). We
also confirmed that miR-22 expression was significantly
reduced in metastasis tumors (P = 0.0034) and advanced
histologic grades (P = 0.0315, Figure 1B,C). Therefore,
we conclude that miR-22 expression is significantly down-
regulated in ESCC at mRNA levels in a manner negatively
associated with aggressive tumor behaviors.
We also detected the miR-22 expression in ESCC and
normal esophageal epithelial cell lines. We performed
real-time RT-PCR on a panel of eight ESCC and one
normal cell line. As showed in Figure 2, miR-22 levels of
all cancer cell lines were lower than that of normal
esophageal epithelial cells (NEEC) (P = 0.003). miR-22
expression in Eca109 and Kyse410 cells was relatively
low. These results have increased our knowledge of the
expression profile of miR-22 in tumor types and this
specific expression mode indicates that miR-22 might
play an important role in ESCC cancer progression.
Over-expression of miR-22 inhibits ESCC cell proliferation
Based on the above results, we detected whether miR-22
can change the capacity of ESCC cells for proliferation.
We transfected Eca109 and Kyse410 cells with miR-22 ex-
pression vector or pcDNA3.1 control, and then evaluatedthe cell growth rate. As expected, transfection of miR-22
expression plasmid into Eca109 and Kyse410 cells resulted
in substantial increase of miR-22 expression compared
with negative control (NC) transfected cells (Figure 3A,
P = 0.023). We performed MTT cell proliferation assays
with transfected miR-22 in Eca109 and Kyse410 cells.
Our results showed that restoration of miR-22 expres-
sion suppressed cell proliferation in both of the ESCC
cell lines (Figure 3B and C).
miR-22 inhibits ESCC cell migration and invasion
In addition to cell growth inhibition, the effect of miR-
22 on tumor migration and invasion was also addressed
in this study. The wound-healing assay showed that
Eca109 and Kyse410 cells with miR-22 overexpression
presented a slower closing of scratch wound, compared
with the negative controls (Figure 4A, P = 0.019 and
P = 0.021). Moreover, the cell migration and invasion assay
showed that miR-22 restoration resulted in reduced migra-
tion rate and invasion rate of Eca109 and Kyse410 cells
Figure 3 Overexpression of miR-22 inhibits proliferation of ESCC cell lines. (A) Transfection of miR-22 expression plasmid to Eca109 and
Kyse410 increases the expression of miR-22 detected by real-time quantitative RT-PCR. *P < 0.05, by one-way ANOVA. (B) and (C) Cell proliferation
of these cells transfected as in A was measured in the indicated time periods using the MTT assay.
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P = 0.011, lower P = 0.027 and P = 0.029). Our results indi-
cate that miR-22 served as a tumor suppressor miRNA
and contributed to inhibition of migration and invasion of
ESCC cells.
Discussion
In our study, we demonstrated that miR-22 expression is
decreased in human ESCC tissues and cell lines com-
pared with matching adjacent non-tumoral tissue and
normal cell lines. The down-expression of miR-22 corre-
lates with ESCC metastatic ability. We also discovered
that miR-22 suppress ESCC cell migration and invasion.
The identification of miR-22 as an essential regulator of
tumor cell migration and invasion in vitro emphasizes
an essential role of this miR-22 in mediating ESCC onco-
genesis and tumor behavior.
ESCC is the fourth most frequently diagnosed cancer
and the fourth leading cause of cancer death in China[12]. Surgical resection is still as the mainstay strategy
employed for operable ESCC. Despite the great advances
has been achieved in multimodal therapy, its five-year
survival rate remains unsatisfactory [5,13]. Discovering
suitable biomarkers will probably be a key to monitoring
cancer recurrence or screening high risk population of
ESCC, giving information on the need for adjuvant or
neoadjuvant therapy.
miRNAs have been demonstrated to have close relation-
ship with ESCC. miR-22, originally identified in HeLa
cells, has been found to be overexpressed in prostate can-
cer, but down-regulated in breast cancer, cholangiocarci-
noma, multiple myeloma, and hepatocellular carcinoma
[14]. In this study, we demonstrated that miR-22 expres-
sion is decreased in human ESCC tissues and cell lines
compared with matching adjacent normal tissues and cell
lines. Restoration of miR-22 in Eca109 and Kyse410 cells
significantly inhibited cellular migration and invasion cap-
ability. Taken together, our results suggest that miR-22 as
Figure 4 Overexpression of miR-22 inhibits migration and invasion of ESCC cell lines. (A) Overexpression of miR-22 presented a slower
closing of scratch wound, compared with miRNA negative control, at 48 h after transfection in Eca109 and Kyse410 cells. (B) The inhibitory effect
of miR-22 toward the invasion and migration of Eca109 and Kyse410 cells. *P < 0.05, by one-way ANOVA.
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gression of ESCC.
Metastasis is a key step of tumor progression in ESCC,
which means a poor prognosis [15]. Metastasis is a series
of sequential events, including detachment, migration,
local invasion, angiogenesis, extravasation, survival in
the circulatory system, extravasation, and regrowth in
different organs [16,17]. Several miRNAs can modulate
tumor metastasis [18]. The identification of miR-22 as
an important regulator of tumor cell migration and inva-
sion in vitro emphasizes an essential role of this miRNA
in mediating ESCC oncogenesis and tumor behavior.
Conclusions
In summary, the present study provides evidence to sup-
port that miR-22, a microRNA downexpressed in ESCC,
inhibits cell migration and invasion of ESCC cells in vitro.
These findings imply that miR-22 might be a suitable can-
didate for anticancer therapy.
Methods
ESCC tissues collection
Thirty paired tissue specimens of ESCC and matched
normal tissues were obtained from Department of
General Surgery in Xiangyang Central Hospital. The
matched "normal tissue" was obtained from a 5 centi-
meter distance from the tumor margin, which were fur-
ther confirmed by pathologist that they do not have
tumor cells. All of the tissues were obtained at the time
of surgery and immediately stored in liquid nitrogen until
use. All individuals provided written informed consent,
and the study was approved by the Ethics Committee of
Xiangyang Central Hospital.
Cell culture
Primary culture of normal esophageal epithelial cells
(NEEC) was established from fresh specimens of the adja-
cent noncancerous esophageal tissue, which is over 5 cm
from the cancerous tissue, according to a previous report
[19,20]. The ESCC cell lines, including Kyse140, Kyse510,
Eca109, TE-1, Kyse410, EC18, HKESC1 and 108CA,
were grown in the Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (FBS) (HyClone, Logan, UT,
USA) at 37°C in a humidified atmosphere of 5% CO2.
Real-time quantitative RT-PCR
Total cellular RNA was extracted using the Trizol re-
agent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instruction. Briefly, about 100 mg ESCC
or adjacent tissues in the liquid nitrogen were preserved
in 2 mL Trizol. Then, the tissues were fully cracked
using the homogenizer. The supernatants were obtained
after 12000 × g, 4°C, centrifugation 5 minutes. Total RNAswere isolated from the supernatants of these samples fol-
lowing the manufacturer’s instructions. Real time PCR was
performed using SYBR Premix Ex Taq™ II Kit (TaKaRa) ac-
cording to the manufacturer’s protocol on an MX3005P
QPCR system (Stratagene, La Jolla, CA, USA). The U6
small nuclear RNA was used as internal control. All of the
reactions were run in triplicate. The delta-Ct method
[21,22] for relative quantification of gene expression was
used to determine miRNAs expression levels. Forward and
reverse primers for miR-22, u6 snRNA, were 5’-AAG CTG
CCA GTT GAA GAA CTG TA-3’ and Universal Primer
(Qiagen), 5’-CTC GCT TCG GCA GCA CA-3’ and 5’-
AAC GCT TCA CGA ATT TGC GT-3’, respectively. All
primers above were synthesized by Shanghai Sangon
Biological Engineering Technology and Services Co., Ltd
(Shanghai, China).
Plasmid construction
For the expression of miR-22, genomic fragment of Homo
sapiens miR-22 precursor was amplified by PCR using the
primer pairs: 5’- GGG GGA TCC CTG GGG CAG GAC
CCT -3’ and 5’- GGG GAA TTC AAC GTA TCA TCC
ACC C -3’ [23]. The PCR product was cloned into
pcDNA3.1 (Invitrogen, Carlsbad, CA, USA) named as
pcDNA3.1-miR-22. Lipofectamine 2000 (Invitrogen) was
used for DNA plasmid transfection.
Cell proliferation assay
Cells were plated in sextuplicate in 96-well plates (2 × 103
per well) in 100 μL complete medium and allowed to at-
tach overnight. 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) (20 μL at 5 mg/mL;
Sigma, St. Louis, MO) was added every 24 h and incubated
for 4 h. The supernatant was discarded, the precipitate was
dissolved in 200 μL dimethyl sulfoxide (DMSO), and plates
were read with a microplate reader at 570 nm [14].
Wound-healing assay
The wound-healing assay was used to evaluate the tumor
cell motility capacity. Briefly, 1 × 106 cells were seeded in
six-well plates, cultured overnight, and transfected with
miR-22 and control, respectively. When the culture had
reached nearly 90% confluency, the cell layer was scratched
with a sterile plastic tip and then washed with culture
medium twice and cultured again for up to 48 or 72 h with
serum-reduced medium containing 1% FBS. At different
time points, photographic images of the plates were ac-
quired under a microscope and the data were summarized
based on sextuple assays for each experiment.
In vitro invasion assay and migration assay
MilliCell (12 mm diameter with 8 μm pores) chambers
(Millipore, Bedford, MA, USA) were pre-coated with
Matrigel (BD, Bedford, MA, USA) on the upper side. A
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added to the upper compartment in medium supple-
mented with 0.1% serum, and the chambers were placed
into 24-well plates with medium containing 10% serum.
After 24 h at 37°C, invaded cells on the lower membrane
surface were fixed and stained with 0.1% crystal violet.
Invasive activity was quantified by counting nine high-
power fields (HPFs, 400×) per chamber. Mean values
were obtained from at least three individual chambers
for each experimental point per assay. The migration
assay is the same with invasion assay excepting no
Matrigel was used and the permeating time for cells
was 12 hours.
Statistical analysis
All statistical analyses were performed using the SPSS
16.0 statistical software package (SPSS, Chicago, IL, USA).
The significance of the data was determined using
Student’s t test. All the statistical tests were two-sided, and
a P value < 0.05 was considered significant.
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